H2 2025 · Presentation
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ · 31 pages
Read Scancell Holdings Plc's results firsthand
Preview the first 2 pages of this presentation
Create a free account to start reading
Full documents are included with Professional